Nureca Limited has informed the Exchange about General Updates
NURECA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Nureca Limited filed its Q1 FY26 Investor Presentation, reporting revenue of ₹34.17 crore, up 8% QoQ and marking its highest quarterly revenue in the last 10 consecutive quarters. EBITDA grew 98% YoY to ₹42 million, while Profit After Tax stood at ₹8 million, down 3% YoY. The company highlighted its digital-first model with 93% of revenue from online sales, 277+ active SKUs, 9 new product launches in the quarter, and an annual production capacity of over 7 lakh units. The presentation outlined four strategic pillars: D2C growth, pan-India offline distribution (192+ live distributors across 54+ states), in-house manufacturing via USFDA-approved subsidiary Nureca Technologies, and Connected Health through the Dr Trust 360 app (1.7 million users). Nureca reiterated it remains debt-free and asset-light, and flagged a 9.9% CAGR for India's healthcare products market through 2030.
Strong top-line momentum and sharp EBITDA expansion signal improving operating leverage, though muted PAT growth suggests cost pressures or higher spending (advertising spend was ₹212 crore in Q1 FY26). For shareholders, the focus on in-house manufacturing and omni-channel expansion supports the long-term margin story, but near-term profitability tracking will be key to watch.